Difference between revisions of "Crenolanib (CP-868,596)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Investigational" to "Category:Investigational drugs") |
||
Line 5: | Line 5: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
− | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
[[Category:FLT3 inhibitors]] | [[Category:FLT3 inhibitors]] | ||
[[Category:PDGFR inhibitors]] | [[Category:PDGFR inhibitors]] |
Revision as of 17:48, 3 February 2019
In clinical trials
Preliminary Data
- Lewis NL, Lewis LD, Eder JP, Reddy NJ, Guo F, Pierce KJ, Olszanski AJ, Cohen RB. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J Clin Oncol. 2009 Nov 1;27(31):5262-9. Epub 2009 Sep 8. link to original article PubMed